Infraredx, a Nipro Company, Announces Enrollment of First Patient in EXPANSE PTCA study.
The objective of this study is to evaluate safety and effectiveness of the Lacrosse NSE ALPHA coronary dilatation catheter during PCI in subjects with stenotic coronary arteries.
Bedford, Mass., December 22, 2021 — Infraredx, a Nipro Company, a pioneer in intravascular imaging for mapping coronary artery disease, announced today the enrollment of the first patient in its EXPANSE PTCA study (NCT04985773) at the Cardiology Associates of North Mississippi in Tupelo, Mississippi. The study will be conducted in the United States with the objective to evaluate safety and effectiveness of the Lacrosse NSE (Non-Slip Element) ALPHA coronary dilatation balloon catheter during percutaneous coronary intervention (PCI) in patients with stenotic coronary arteries.